Martin Godbout, PhD
Following a brief academic career at the Université Laval in the early 1990s, Martin Godbout was made chief executive officer of the Société Innovatech Québec, a venture capital firm. In 1997, he continued in the field of biopharmaceutical venture capital and went on to become executive vice-president of BioCapital. In May of 2000 he becomes the founder, president and chief executive officer of Genome Canada, which he leads for nearly ten years. Officer of the Order of Canada (2005), he is currently the chairman of the board of directors for AmorChem and OptiThéra, and a member of the board of directors for AngioChem, Endoceutics, P3G, the Charlevoix-Saguenay Ataxia Foundation, Inno-centre and the Baie Saint-Paul Hospital Foundation. In addition, over the course of his career he has acted as independent director for the boards of the following organizations: Acasti Pharma, Asmacure, BASE4 Bioinformatics, BCM, Biovet, Chelation Partners, Chronogen, Cifra Médical, Diagnocure, Innovatech of the Greater Montreal, Laboratoires Confab, MethylGene/Mirati, Néokimia, SGF-santé, and of the following NPOs : BioContact, BIOQuébec, BIOTECanada, NSERC, Fonds Recherche Québec – Santé, Genome Canada/Genome Quebec, IRICoR, Montréal InVivo, Precinomics, the Foundation of Stars and the Leukodystrophies Foundation.
Martin Godbout holds a Ph.D in physiology and molecular endocrinology from the Université Laval. He then went on to become a post-docoral fellow working in molecular neurobiology at the Scripps Research Institute of San Diego.